Tyra Biosciences Pipeline & Targets

TYRA-300 is being developed to improve quality of life for individuals with skeletal dysplasia, including achondroplasia, caused by FGFR3 gene mutations. The drug, informed by FGFR crystal structures, is in Phase 2, with dosing starting Q1 2025.